Introduction {#s0001}
============

In 2002, the US Women's Health Initiative (WHI) reported that menopausal hormone therapy (MHT) was associated with an increased risk of breast cancer, cardiovascular disease and thromboembolic events[@CIT0001]. The negative publicity that ensued alarmed many women and their clinicians, resulting in a decrease in MHT use across the world[@CIT0002]. A similar trend was observed in postmenopausal women taking part in the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS); MHT use decreased in women recruited in 2005 (10--11%) compared with those recruited in 2001 (29%)[@CIT0007].

Complementary and alternative medicine (CAM) for menopausal symptom relief is by definition not considered part of conventional medicine[@CIT0008]. The lay public regard them as being 'fairly safe'[@CIT0009]. They can include approaches such as herbal therapies, phytoestrogens, and non-pharmacological interventions (NPI) such as exercise, acupuncture and yoga. Cognitive behavior therapy is considered part of conventional medicine and has been recommended by the National Institute of Health and Care Excellence (NICE) for management of low mood associated with the menopause[@CIT0010].

Two systematic reviews of use of CAM therapies for menopausal symptoms have been published. The first in 2013, based on nine studies with a total of 32 465 menopausal women, reported that 50.5% used CAM therapies/NPI for relief of menopausal symptoms[@CIT0011]. The more recent 2014 meta-analysis restricted eligible studies to those involving more than 500 women and reported a CAM/NPI prevalence ranging from 31% to 82.5%[@CIT0012]. Both reviews conclude that many surveys were of poor methodological quality, making it difficult to estimate the true prevalence of CAM/NPI use among climacteric women[@CIT0011] ^,^ [@CIT0012].

Data from the UK are limited to three surveys, two of which were undertaken in 2001 before the publication of the WHI results. The remaining survey dates from 2006 involving 563 women. The overall prevalence of CAM/NPI use was not reported but the prevalence of each CAM therapy ranged from 1.2% for hypnosis to 39.6% for vitamins[@CIT0013].

Higher income, education and socioeconomic status have been shown to predict CAM/NPI use[@CIT0014] ^,^ [@CIT0015] with CAM/NPI consumers also using more conventional therapies than women not using CAM/NPI. Other factors associated with use of CAM/NPI therapies in the UK are White ethnicity, being physically active and a non-smoker[@CIT0013].

We report on the prevalence and predictors of CAM and NPI use for relief of menopausal symptoms in a large UK cohort of postmenopausal women participating in UKCTOCS.

Methods {#s0002}
=======

Study participants {#s0003}
------------------

UKCTOCS is a randomized controlled trial designed to assess the impact on mortality of ovarian cancer screening. Between April 2001 and October 2005, postmenopausal women aged 50--74 were randomly invited from age-sex registers and 202 638 enrolled through 13 trial centers located in NHS Trusts in England, Wales and Northern Ireland. Further details on the study design have been reported elsewhere[@CIT0016]. Postmenopausal status in these women aged over 50 was defined as \>12 months amenorrhea following a natural menopause or hysterectomy or \>12 months of MHT commenced for menopausal symptoms.

All women completed a baseline questionnaire at recruitment which included questions on current use of MHT, date of last period, age at first menstrual period, oral contraceptive pill (OCP) use, hysterectomy, sterilization, infertility, pregnancies lasting less or more than 6 months, personal history of cancer and family history of ovarian and breast cancer.

All women were followed up with a postal questionnaire (FUQ) 3--5 years after randomization. From September 2006, the FUQ included the question 'Have you used any of the following to relieve menopausal symptoms?' (yes or no) with a tick for each of the following: (1) herbal remedies, e.g. black cohosh; (2) phytoestrogens or soy products; (3) vitamins, e.g. Menopace, vitamin E; (4) homeopathic remedies; (5) aromatherapy, reflexology or acupuncture; (6) lifestyle changes, e.g. relaxation, exercise; or (7) other medical treatments, e.g. Venlafaxine, Megace.

Also included in the FUQ were questions on education, alcohol use, smoking, chronic diseases (diabetes, high blood pressure, high cholesterol, heart disease, stroke, rheumatoid arthritis, osteoarthritis, osteoporosis), cancers diagnosed after trial entry, and current MHT use. Women's broad expectations about the future and their perceived ability to attain personal goals were assessed with two statements: 'The future seems to me to be hopeful, and I believe that things are changing for the better' and 'I feel that it is possible to reach the goals I would like to strive for'. Women were asked to indicate the extent to which they agreed with each statement using a 5-item scale from 'absolutely agree' to 'absolutely disagree' where higher scores indicate higher levels of hopelessness. This positively phrased measure of hopelessness has been shown to be valid and reliable in postmenopausal women in the UK[@CIT0017].

Ethical approval for the study was received from the UCL/UCLH Committees on the Ethics of Human Research, Committee A on 30th May 2006 (REC 06/Q0505/36).

Statistical analysis {#s0004}
--------------------

### Predictors of CAM/NPI use {#s0005}

With regard to the demographic variables, erroneous heights \<120 cm and \>210 cm and weights \<30 and \>200 kg were discarded and the data field set as missing. The body mass index (BMI) was either grouped as: underweight (\< 20 kg/m^2^); normal weight (≥20 and \<25 kg/m^2^); overweight (≥25 and \<30 kg/m^2^); obese (≥30 and \<40 kg/m^2^); and morbidly obese (≥ 40 kg/m^2^) or used as a continuous variable. Ethnicity was grouped as White, Black (which included Black African, Black Caribbean and Black Other), South Asian (Indian, Pakistani and Bangladeshi) and Other. Education was grouped as Higher education (college/university), Other formal qualification (nursing and teaching, 'O' level or equivalent, 'A' level or equivalent and clerical or commercial qualification) or No formal qualification (other than compulsory education). Women who had stated that they had both college/university degree and no formal education (*n* = 120) were grouped under college/university.

Use of CAM/NPI (yes/no and type) were examined by age group, ethnicity, education, BMI, OCP use, MHT use, hysterectomy, sterilization, number of pregnancies and cancer history.

For the women residing in England, an Index of Multiple Deprivation (IMD) score based on the women's postcode derived at the Super Output Area level was available and used as a proxy for the socioeconomic status. For reasons of model interpretation, the IMD score was standardized to have a standard deviation of one.

Women who had used both CAM/NPI and 'other medical treatments' were not included in the model, but were adjusted for in the regression analysis.

### Multivariate probit model of predictors of CAM/NPI use for women residing in England {#s0006}

To examine the associations between the six different types of CAM/NPI, tetrachoric correlations of CAM/NPI type use were calculated, which estimate the correlation between two theorized normally distributed latent variables (here the propensity for CAM/NPI type use) using observed dichotomous variables. Similarly to other correlational measures, possible values ranged from −1 (negative correlation) to +1 (positive correlation). To model the effect of the various factors on the probability of each CAM/NPI type use, it was necessary to account for the likelihood that CAM/NPI use for one type will be highly (positively) correlated with each of the other CAM/NPI types. For this reason, a multivariate probit model was fitted (with the user-written command mvprobit in Stata[@CIT0018]) which preserved this correlational structure in the six-dimensional response variable.

Age (stratified per 5-year age groups), BMI (per 5 kg/m^2^), age at first menstrual period (FMP, per 5 years), age at last menstrual period (LMP, per 5 years), hopelessness (HH, per unit SD), IMD score (per unit SD), number of pregnancies \<6 months and number of pregnancies \>6 months were modeled as continuous variables. Univariate probit models were used to check the functional form and demonstrate that linearity (in the probit scale) was a reasonable assumption.

As probit model parameters are not easily interpretable, marginal effects were estimated using Stata's *margin* and *lincom* commands. Given that the model had 180 parameter estimates, the marginal effect (with 95% confidence interval (CI)) on each CAM/NPI type was also plotted in variable groupings to improve interpretation. Formal hypothesis testing was not considered due to the number of model estimates.

Results {#s0007}
=======

Between September 2006 and May 2009, 136 020 postmenopausal women taking part in UKCTOCS were sent a follow-up questionnaire assessing use of CAM/NPI for relief of menopausal symptoms; 96 428 women returned a questionnaire (70.9%). A total of 7057 women were excluded from the analysis as the questionnaire completion date was missing. Of the remaining 89 371 participants, 941 had used 'other medical treatment' and were excluded. The final cohort included 88 430 (65.0%) cases. The overall median age was 64.7 years, with all women aged over 51 at completion of the survey; 97.4% (86 116/88 430) were White and 21.4% (18 902/88 430) had a higher education ([Table 1](#t0001){ref-type="table"}).

###### 

Demographics of the study women and those using complementary and alternative medicine (CAM)/non-pharmacological interventions (NPIs) for menopausal symptom relief.

                                                              *Ever use of CAM*                                                                                                              
  ----------------------------------------------------------- ------------------- ------- -------- ------- ------- ------- ------- ------- ------- ------- ------ ----- ------ ------ ------ ------
  *Age at reporting* (years)                                                                                                                                                                  
  50--54                                                      2489                2.8     1051     42.2    566     22.7    119     4.8     282     11.3    160    6.4   503    20.2   328    13.2
  55--59                                                      19 063              21.6    7771     40.8    4087    21.4    918     4.8     1993    10.5    1114   5.8   3364   17.6   2456   12.9
  60--64                                                      23 965              27.1    7226     30.2    3183    13.3    898     3.7     1550    6.5     1006   4.2   3160   13.2   2194   9.2
  65--69                                                      20 422              23.1    3886     19.0    1333    6.5     534     2.6     667     3.3     597    2.9   1589   7.8    1294   6.3
  70--74                                                      16 200              18.3    1776     11.0    474     2.9     248     1.5     249     1.5     273    1.7   662    4.1    640    4.0
  75+                                                         6291                7.1     496      7.9     82      1.3     74      1.2     61      1.0     86     1.4   180    2.9    225    3.6
  All ages                                                    88 430              100.0   22 206   25.1    9725    11.0    2791    3.2     4802    5.4     3236   3.7   9458   10.7   7137   8.1
  *Overall use of each therapy*                                                           25.1%    11.0%   3.2%    5.4%    3.7%    10.7%   8.1%                                              
  *Overall use in those using CAM*                                                                         43.8%   12.6%   21.6%   14.6%   42.6%   32.1%                                     
  *Ethnicity*                                                                                                                                                                                 
  White                                                       86 116              97.4    21 441   24.9    9470    11.0    2712    3.1     4650    5.4     3142   3.6   9112   10.6   6789   7.9
  Black                                                       760                 0.9     294      38.7    102     13.4    28      3.7     51      6.7     34     4.5   150    19.7   133    17.5
  South Asian                                                 408                 0.5     130      31.9    34      8.3     20      4.9     22      5.4     10     2.5   48     11.8   74     18.1
  Other                                                       746                 0.8     255      34.2    79      10.6    22      2.9     61      8.2     35     4.7   114    15.3   114    15.3
  Missing                                                     400                 0.9     86       21.5    40      10.0    9       2.3     18      4.5     15     3.8   34     8.5    27     6.8
  *Education*                                                                                                                                                                                 
  College/university or equivalent                            18 902              21.4    5869     31.0    2514    13.3    828     4.4     1543    8.2     976    5.2   2429   12.9   2328   12.3
  Other formal qualification                                  44 233              50.0    11 990   27.1    5356    12.1    1479    3.3     2588    5.9     1785   4.0   5194   11.7   3787   8.6
  None                                                        23 953              27.1    4078     17.0    1753    7.3     452     1.9     633     2.6     450    1.9   1722   7.2    943    3.9
  Missing                                                     1342                1.5     269      20.0    102     7.6     32      2.4     38      2.8     25     1.9   113    8.4    79     5.9
  *Smoking*                                                                                                                                                                                   
  Have smoked/smoker                                          37 863              42.8    9873     26.1    4510    11.9    1296    3.4     2102    5.6     1435   3.8   4255   11.2   3103   8.2
  *Body mass index* (kg/m^2^)                                                                                                                                                                 
  Underweight (11--19)                                        3198                3.6     830      26.0    339     10.6    112     3.5     223     7.0     112    3.5   367    11.5   271    8.5
  Normal (20--24)                                             35 245              39.9    9778     27.7    4368    12.4    1204    3.4     2420    6.9     1274   3.6   4291   12.2   3281   9.3
  Overweight (25--29)                                         32 142              36.3    7804     24.3    3444    10.7    987     3.1     1552    4.8     1196   3.7   3227   10.0   2451   7.6
  Obese (30--39)                                              15 522              17.6    3297     21.2    1392    9.0     420     2.7     520     3.4     567    3.7   1365   8.8    972    6.3
  Morbidly obese (40+)                                        1341                1.5     261      19.5    99      7.4     44      3.3     37      2.8     51     3.8   116    8.7    76     5.7
  Missing/erroneous                                           982                 1.1     236      48.0    83      16.7    24      5.0     50      9.8     36     7.5   92     18.7   86     17.6
  *OCP (ever use)*                                            54 793              62.0    16 091   29.4    7561    13.8    2032    3.7     3644    6.7     2394   4.4   6875   12.5   5054   9.2
  *MHT (ever use)*                                            14 454              16      5319     36.8    2769    19.2    619     4.3     1301    9.0     766    5.3   2204   15.2   1553   10.7
  *History of hysterectomy*[^a^](#TF2){ref-type="table-fn"}   15 432              17.5    3950     25.6    1762    11.4    486     3.1     882     5.7     636    4.1   1585   10.3   1217   7.9
  *Tubal ligation*                                            17 968              20.3    4730     26.3    2080    11.6    582     3.2     961     5.3     712    4.0   1995   11.1   1446   20.3
  *Pregnancies \<6 months*                                                                                                                                                                    
  0                                                           60 905              68.9    14 809   24.3    6504    10.7    1842    3.0     3109    5.1     2072   3.4   6233   10.2   4646   7.6
  1                                                           18 045              20.4    4741     26.3    2046    11.3    602     3.3     1059    5.9     728    4.0   2073   11.5   1576   8.7
  2                                                           5359                6.1     1575     29.4    694     13.0    200     3.7     377     7.0     262    4.9   667    12.4   546    10.2
  3                                                           1764                2.0     477      27.0    211     12.0    71      4.0     132     7.5     79     4.5   211    12.0   177    10.0
  4+                                                          1314                1.5     360      27.4    170     12.9    47      3.6     83      6.3     65     4.9   174    13.2   109    8.3
  Missing                                                     1043                1.2     244      23.4    100     9.6     29      2.8     42      4.0     30     2.9   100    9.6    83     8.0
  *Parity -- pregnancies \>6 months*                                                                                                                                                          
  0                                                           10 610              12.0    2979     28.1    1420    13.4    441     4.2     772     7.3     517    4.9   1250   11.8   936    8.8
  1                                                           10 402              11.8    2719     26.1    1230    11.8    371     3.6     621     6.0     437    4.2   1150   11.1   844    8.1
  2                                                           38 687              43.7    10 297   26.6    4598    11.9    1228    3.2     2197    5.7     1372   3.5   4427   11.4   3339   8.6
  3                                                           19 559              22.1    4419     22.6    1767    9.0     527     2.7     876     4.5     652    3.3   1887   9.6    1414   7.2
  4+                                                          8 993               10.2    1746     19.4    691     7.7     220     2.4     328     3.6     254    2.8   724    8.1    585    6.5
  Missing                                                     179                 0.2     46       25.7    19      10.6    4       2.2     8       4.5     4      2.2   20     11.2   19     10.6
  *Cancer history*[^b^](#TF2){ref-type="table-fn"}            6 878               7.8     1443     21.0    527     7.7     217     3.2     289     4.2     270    3.9   592    8.6    480    7.0
  History of breast cancer                                    4 780               5.4     1008     21.1    359     7.5     152     3.2     218     4.6     188    3.9   410    8.6    337    7.1
  History of bowel cancer                                     648                 0.7     110      17.0    44      6.8     18      2.8     22      3.4     17     2.6   43     6.6    33     5.1
  History of gynecological  (ovarian/endometrial) cancer      376                 0.4     84       22.3    39      10.4    14      3.7     12      3.2     17     4.5   31     8.2    24     6.4

OCP, oral contraceptive pill; MHT, menopausal hormone therapy

, Reported at recruitment; ^b^, history of cancer captured at recruitment (breast, bowel, lung, other), or (breast, bowel, gynecological) at follow-up questionnaire

Ever-use of CAM/NPI {#s0008}
-------------------

Of all the women who completed the questionnaire, 25.1% (22 206/88 430) reported 'ever-use' of at least one of the six types of CAM/NPI for menopausal symptom relief ([Table 1](#t0001){ref-type="table"}). The prevalence of CAM/NPI use across responders ranged from 3.2% (2791/88 430) for homeopathy to 11.0% (9725/88 430) for herbal remedies. In those reporting CAM/NPI use, the most commonly used therapies were herbal remedies (43.8%; 9725/22 206), vitamins (42.6%; 9458/22 206) and lifestyle changes (32.1%; 7137/22 206) followed by phytoestrogens (21.6%; 4802/22 206). A smaller percentage of women used aromatherapy/reflexology/acupuncture (ARA) (14.6%; 3236/22 206) and homeopathy (12.6%; 2791/22 206) ([Table 1](#t0001){ref-type="table"}).

Of the 4780 (5.4%) who reported a history of breast cancer, 8.3% (396/4780) had used MHT and 21.1% (1008/4780) had used one of the CAM/NPI.

Of the women who had ever-used CAM/NPI, 57.6% (12 799/22 206) indicated they had only used one type of therapy, with herbal remedies being most frequently used (3965), 25.9% (5756/22 206) had used two therapies with a combination of herbal remedies and vitamins (1254) most commonly used. Three or more therapies were used by 16.4% (3651/22 206) of the women (data not shown).

Correlations between CAM/NPI types {#s0009}
----------------------------------

Correlations between the six different types of CAM/NPI were examined using tetrachoric correlations. All observed correlations were strong, with a minimum of 0.39 (herbal and lifestyle) and a maximum of 0.64 (herbal and phytoestrogens). Other correlations over 0.6 were for ARA and homeopathy (0.61) and lifestyle and ARA (0.63). These unadjusted tetrachoric correlations are shown in the lower triangle of Supplementary Table S1 (see <http://dx.doi.org/10.1080/13697137.2017.1301919>). The upper triangle gives the between CAM/NPI type correlations estimated following adjustment from the model and are largely similar to the unadjusted correlations, though mostly slightly lower.

Predictors of CAM/NPI use {#s0010}
-------------------------

Due to the inclusion of the deprivation (IMD) variable based on women who resided in England, the modeling was restricted to 66 577 cases. There were missing covariate data in 7053 cases and excluding these meant that 59 524 cases were included in the final model. For each potential predictor, [Figure 1](#F0001){ref-type="fig"} depicts the estimated effect on probability of ever-use of each CAM/NPI type for a unit change in that predictor, with 95% CIs. The actual values that underlie this plot are presented in Supplementary Table S2 (see <http://dx.doi.org/10.1080/13697137.2017.1301919>), and the original model estimates in the probit scale are presented in Supplementary Table S3 (see <http://dx.doi.org/10.1080/13697137.2017.1301919>).

![Effect on the probability of each type of CAM/NPI use for a unit change in each predictor variable. Herbal, herbal remedies; Homeopathic, homeopathic remedies; Phytoestrogens, phytoestrogens or soy products; Aromatherapy, aromatherapy, reflexology or acupuncture; Lifestyle, lifestyle changes; FMP, first menstrual period; LMP, last menstrual period; HH, hopelessness scale; IMD, index of multiple deprivation; BMI, body mass index; HRT, hormone therapy; pill, oral contraceptive pill.](icmt_a_1301919_f0001_c){#F0001}

There was a wide range of effect across the predictors with some having an unequivocal effect on CAM/NPI use and some being only minimally related to CAM/NPI use. In addition, it was notable that some predictors had a consistent effect across the six CAM/NPI types whilst others had a discrepant effect. In general, the predictors for herbal remedies were often quite different to those for the other CAM/NPIs, an effect which was also observed for lifestyle changes but to a lesser extent.

Age was a strong negative predictor of ever-use of CAM/NPI types, especially herbal remedies (each 5-year increase in age reduced ever-use by 5.4% (95% CI 5.1--5.7%) ([Figure 1](#F0001){ref-type="fig"}). This is also apparent in the overall set of 22 206 women ([Table 1](#t0001){ref-type="table"}). With increasing age, there was a decline in ever-use of herbal remedies and vitamins and a less pronounced decline in ever-use of phytoestrogens ([Figure 1](#F0001){ref-type="fig"}). The uses of ARA, homeopathy and lifestyle change were similar across all the age groups ([Figure 1](#F0001){ref-type="fig"}).

Other consistently negative predictors were BMI (each additional 5 kg/m^2^ reduced most CAM/NPI type use by around 1%), high blood pressure and diabetes. Hopelessness (HH) had a small but clear negative effect on use of all CAM/NPI types. Women who had a low HH score (more hopeful) were more likely to use any CAM/NPI to relieve menopausal symptoms, with lifestyle changes being the most likely. Interestingly, the number of full-term pregnancies had a consistent negative effect across CAM/NPI types, whereas the number of pregnancies under 6 months had a consistent positive effect on CAM/NPI usage (around 0.5% per pregnancy).

Age at last menstrual period had a consistent positive effect on CAM/NPI usage (ranging from 0.2% for ARA to 1.4% for herbal remedies for each 5-year increase). Other clear positive effects were also found with osteoarthritis, MHT use (though much higher for herbal remedies), higher education (though much higher for lifestyle changes), other formal qualifications and being of Black ethnicity. OCP use had a positive effect on all CAM/NPI types but the effect was only unequivocal for herbal remedies (1.8%; 95% CI 1.2--2.4%).

Some predictors had a less consistent effect across the six CAM/NPI types, notably previous cancer only negatively affecting use of herbal remedies and to a lesser extent vitamins, and both osteoporosis, South Asian and 'Other' ethnicity appearing to have a negative effect on use of herbal remedies and a positive effect on lifestyle changes.

Discussion {#s0011}
==========

In our study of over 88 000 postmenopausal women, which to our knowledge is the largest report on the subject, one in four women used at least one CAM therapy/NPI for menopausal symptom relief. Herbal therapies and vitamins were most commonly used followed by lifestyle approaches. Higher levels of education and previous MHT use were positive predictors of CAM/NPI use while women who were overweight or obese, had diabetes/hypertension or held less hopeful views about the future and their ability to achieve personal goals were less likely to use CAM/NPI.

Previous studies have reported CAM use to range from 24% to 91%[@CIT0013]. The prevalence in our study (25%) was markedly lower than the 57% reported in a recent meta-analysis of three UK studies involving 3742 climacteric women[@CIT0014]. However, two of these studies were undertaken prior to the publication of the WHI results in 2002.

Herbal remedies were most commonly used, as reported in other studies[@CIT0019], followed by vitamins and lifestyle changes. This trend persisted on subgroup analysis restricted to women who had only used one approach and is in keeping with results of a 2013 systematic review[@CIT0011]. It needs to be noted, however, that some of the vitamin preparations may have contained phytoestrogens. One in five of the CAM users opted for a lifestyle change while one in four used at least two different types of CAM.

The association of age with type of CAM/NPI use for menopausal symptom relief is likely to be a cohort effect. Women of all age groups reported similar use of aromatherapy/reflexology/acupuncture, homeopathy and lifestyle changes for relief of menopausal symptoms. These approaches have been in use since the 1960s and are therefore likely to have been available when older women in our cohort were going through the menopause. In contrast, younger women reported higher ever-use of herbal remedies, vitamins and phytoestrogens, reflecting the more recent popularity of these regimes.

Consistent with the existing literature[@CIT0019] ^,^ [@CIT0022], higher education positively influenced CAM/NPI use. This may reflect a greater propensity to seek out health information (books, magazines, internet), leading to greater knowledge on the availability of CAM for menopausal symptom relief[@CIT0021]. Alternatively, as women with a higher level of education have been shown to have less severe hot flushes and night sweats[@CIT0025], it is possible that milder symptoms may have contributed to the decision to use CAM/NPI rather than MHT.

The financial cost of these therapies is known to influence women's choices[@CIT0026]. However, our data do not show a clear association between socioeconomic status, based on the deprivation (IMD) score, and use of CAM therapies/NPI for menopausal symptoms, which is at odds with previous reports[@CIT0014] ^,^ [@CIT0027] ^,^ [@CIT0028]. Only phytoestrogens, and to some extent lifestyle changes, were less likely to be used with increasing deprivation.

A variety of other factors predicted CAM/NPI use with some having an unequivocal effect whilst others had only a minimal impact. Interestingly, predictors of herbal remedy use were often quite different to the others. In contrast to the results reported by the Study of Women's Health across the Nation (SWAN)[@CIT0014], we found higher BMI to be negatively associated with ever use of CAM/NPI. A similarly negative correlation was also seen in those reporting hypertension and diabetes. CAM/NPI users have previously been described to smoke less[@CIT0029] but we were not able to confirm this in our cohort. Although being of Black ethnicity was a strong predictor of CAM/NPI use, there were only 294 women in this group representing 1.3% of CAM/NPI users.

There is a large body of evidence suggesting that hopelessness is related to the development and outcome of mental and physical health conditions, ranging from depression to cardiovascular disease and cancer[@CIT0030]. Women who were less hopeful about the future and their ability to attain personal goals were less likely to use any CAM/NPI and had the lowest use of lifestyle approaches to relieve menopausal symptoms. Previous studies have suggested that people who see their medical symptoms as an opportunity for personal development and learning are more likely to use CAMs[@CIT0038]. Furthermore, studies in cancer patients have shown that many consider use of CAMs in addition to standard medical methods as one way of coping and actively addressing feelings of hopelessness[@CIT0039].

Use of MHT (as in the SWAN study)[@CIT0027] and OCP positively predicted CAM/NPI ever use with the largest effect seen for herbal remedies. It is likely that women who are proactive in taking medicines to take control of their health are more likely to use CAM/NPI. Many women in our cohort stopped using MHT following the negative publicity of the 2002 WHI results[@CIT0001]. It is possible that these women subsequently chose CAM/NPI as an alternative for menopausal symptom relief[@CIT0040].

Despite the negative publicity surrounding MHT and the initial scare about an increase in breast cancer risk, previous cancer history did not predict overall CAM/NPI use. Of the women with breast cancer history, 21% reported use of any CAM/NPI type, which is similar to the usage across the entire cohort. This is in keeping with the recommendation that women with a history of breast cancer should consider non-hormonal options[@CIT0041].

Since the initial WHI report, the re-analysis of the trial data[@CIT0042] and subsequent studies have shown very beneficial risk--benefit ratios for healthy women aged 50--60 years. In 2016, the International Menopausal Society[@CIT0043] and NICE[@CIT0044] issued comprehensive guidance on use of MHT that reflects this revised perspective. It is likely that this may reverse the cycle of falling MHT and increasing CAM/NPI use. Currently, the North American Menopause Society only recommends cognitive behavioral therapy and clinical hypnosis as non-hormonal, non-medicinal approaches for menopausal symptom relief[@CIT0045].

Strengths and limitations {#s0012}
-------------------------

A key strength of our study is its size. The findings are likely to be more representative of CAM/NPI use in postmenopausal women in the general population, as self-selection bias in this large cohort taking part in a screening trial is likely to be less than in small studies focusing on the menopause. It is also likely that self-reporting in a clinical trial setting facilitated reporting of CAM/NPI use, as reports suggest that 55--72% of women do not wish to discuss/disclose CAM use to their health-care professionals[@CIT0046] ^,^ [@CIT0047]. A limitation in keeping with all patient surveys is that the reported CAM/NPI prevalence could have been influenced by a healthy volunteer effect[@CIT0048]. We also had an overrepresentation of White ethnicity in our cohort (97%) compared with the 2011 Census (92.1%)[@CIT0049]. While we have not reported on the duration of use and efficacy of CAM/NPI across the whole cohort, this has been reported in a subgroup of 10 000 participants who consented to a more detailed study[@CIT0040].

Conclusion {#s0013}
==========

One in four postmenopausal women in the UK reported use of CAM/NPI for relief of menopausal symptoms, with herbal remedies being most commonly used. Higher CAM/NPI use was reported by women currently in their fifties and sixties. Higher education, Black ethnicity, MHT and OCP use were associated with higher CAM/NPI use while increasing BMI and diabetes/hypertension were associated with less use. Women who were less hopeful about the future and their ability to attain personal goals were less likely to use any type of CAM/NPI and had the lowest use of lifestyle approaches to relieve menopausal symptoms.

Supplementary Material
======================

###### 1301919_Suppl_data.zip

###### 

Click here for additional data file.
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